Gillessen S, Attard G, Beer TM, et al. - This study was undertaken to show the outcomes from the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Researchers distinguished 10 important areas of disagreement regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. This study included a panel of 72 international prostate cancer experts who developed the programme and the consensus questions. These voting outcomes from a panel of prostate cancer experts can support clinicians and individuals navigate controversial areas of advanced prostate management for which high-level data is sparse. Nevertheless, diagnostic and treatment decisions should always be individualised based on individual-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical data and logistic and economic compulsions.